The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis

References

• Shamloul R, Ghanem H. Erectile dysfunction. Lancet 2013;381:153-65
   PubMed Web of Science ®Google Scholar
• Bener A, Al-Hamaq AO, Kamran S, et al. Prevalence of erectile dysfunction in male stroke patients, and associated co-morbidities and risk factors. Int Urol Nephrol 2008;40:701-8
   PubMed Web of Science ®Google Scholar
• Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
   PubMed Web of Science ®Google Scholar
• Mulhall J, King R, Glina S, et al. Importance of and satisfaction with sex among men and women worldwide: results of the global better sex survey. J Sex Med 2008;5:788-95
   PubMed Web of Science ®Google Scholar
• Wessells H, Joyce GF, Wise M, et al. Erectile dysfunction. J Urol 2007;177:1675-81
   PubMed Web of Science ®Google Scholar
• Tomlinson J, Wright D. Impact of erectile dysfunction and its subsequent treatment with sildenafil: qualitative study. BMJ 2004;328:1037
   PubMed Web of Science ®Google Scholar
• Wagner G, Fugl-Meyer KS, Fugl-Meyer AR. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Impot Res 2000;12(Suppl 4):S144-6
   PubMedGoogle Scholar
• Guest JF, Das Gupta R. Health-related quality of life in a UK-based population of men with erectile dysfunction. Pharmacoeconomics 2002;20:109-17
   PubMed Web of Science ®Google Scholar
• Althof SE. Quality of life and erectile dysfunction. Urology 2002;59:803-10
   PubMed Web of Science ®Google Scholar
• Montague D, Jarow J, Broderick G, et al. Erectile Dysfunction Guideline Update Panel. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol 2005;174:230-9
   PubMed Web of Science ®Google Scholar
• Wespes E, Amar E, Hatzichristou D, et al. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006;49:806-15
   PubMed Web of Science ®Google Scholar
• Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013;63:902-12
   PubMed Web of Science ®Google Scholar
• Stendra (avanafil) tablets prescribing information. Mountain View, California: Vivus Inc., 2012
   Google Scholar
• Wang R, Burnett AL, Heller WH, et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med 2012;9:2122-9
   PubMed Web of Science ®Google Scholar
• Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 2004;16(Suppl 1):S11-14
   PubMed Web of Science ®Google Scholar
• Goldstein I, Jones LA, Belkoff LH, et al. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clinic Proceedings Mayo Clinic 2012;87:843-52
   PubMed Web of Science ®Google Scholar
• Zhao C, Kim SW, Yang DY, et al. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. BJU Int 2012;110:1801-6
   PubMed Web of Science ®Google Scholar
• Belkoff LH, McCullough A, Goldstein I, et al. An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction. Int J Clin Pract 2013;67:333-41
   PubMed Web of Science ®Google Scholar
• Goldstein I, McCullough AR, Jones LA, et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med 2012;9:1122-33
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Burnett AL, Wang R, et al. A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. J Urol 2013;189:2229-36
   PubMed Web of Science ®Google Scholar
• Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011
   Google Scholar
• Guyatt GH, Oxman AD, Kunz R, et al. What is ‘quality of evidence’ and why is it important to clinicians? BMJ 2008;336:995-8
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomized Controlled Trials (last updated April 2012). National Institute for Health and Clinical Excellence, 2011
   Google Scholar
• Dias S, Sutton AJ, Welton NJ, et al. NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, Meta-Regression, Bias and Bias-Adjustment (last updated April 2012). National Institute for Health and Clinical Excellence, 2011
   Google Scholar
• Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009;338:b1147
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials (last updated April 2012). National Institute for Health and Clinical Excellence, 2011
   Google Scholar
• Mochida H, Yano K, Inoue H, et al. Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs. J Urol 2013;190:799-806
   PubMed Web of Science ®Google Scholar
• Jung J, Choi S, Cho SH, et al. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. Clin Therapeut 2010;32:1178-87
   PubMed Web of Science ®Google Scholar
• Jung JA, Choe SM, Cho SH, et al. Evaluation of the pharmacokinetics and safety/tolerability of avanafil, a novel phosphodiesterase type 5 inhibitor in healthy Korean subjects. Clin Pharmacol Ther 2008;83:S27
   Web of Science ®Google Scholar